PLX

Rating neutralAI MemoPost-earnings T+3

Protalix Biotherapeutics

As of 2026-05-16/Post-earnings T+3/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-05-16 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

neutral

Confidence

medium

Horizon

6‑12m

Key catalyst

PRX-115 Phase 2 execution remains the main pipeline value driver • 2027-09-30

Expected move: +5%

Biggest risk

The quality of the beat is still mixed because most of the profit swing came from the $25.0 million Chiesi milestone rather than broad-based recurring sales growth. Product revenue fell year over year, management explicitly tied part of the decline to Pfizer order timing, and PRX-115 remains a long-dated clinical asset rather than a near-term de-risked cash generator.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

The post-earnings company update is better than the prior baseline because Protalix reaffirmed full-year revenue guidance, reported a materially stronger cash position, and kept PRX-115 enrollment on track. Secondary market sources also indicated the quarter beat consensus on EPS and revenue, though exact low-coverage consensus figures were inconsistent across checked aggregators.

Research note

Recommendation

neutral

Confidence

medium

As of

2026-05-16

Base target

p=50%

Bull target

p=25%

Bear target

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 milestone-driven beat now has to convert into cleaner underlying commercial demand
Stronger cash balance lowers immediate financing pressure but does not remove biotech runway risk
The post-earnings company update is better than the prior baseline because Protalix reaffirmed full-year revenue guidance, reported a materially stronger cash position, and kept PRX-115 enrollment on track.

BearKey bullets

Commercial revenue remains concentrated in partners and can be distorted by ordering cadence, especially Pfizer and Chiesi timing.
PRX-115 value realization depends on successful Phase 2 execution with topline data not expected until the second half of 2027.
Q1 profit was milestone-driven, so recurring revenue quality remains less impressive than the headline earnings swing.

WatchKey bullets

PRX-115 Phase 2 execution remains the main pipeline value driver

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Post-earnings T+3

Base case: $2 (p=50%)

Bull/Bear spread: +52% / -48%

Vs latest close: Bull +52% · Base +5% · Bear -48%

Scenario probabilities

Bull Target: $3 (p=25%)Base Target: $2 (p=50%)Bear Target: $1 (p=25%)

Commentary

This remains a cautious monitoring setup rather than a high-conviction bullish biotech call. Primary evidence improved on May 13, 2026 because the company 8-K and attached release confirmed the earnings print, reaffirmed 2026 guidance, highlighted the $25.0 million Chiesi milestone, and showed $51.1 million of quarter-end cash [#8-K-2026-05-13] [#10-Q-2026-05-13]. But low coverage still matters: checked sources did not show a strong analyst revision wave after the print, consensus data was thin across aggregators, peers remain loose, and by the 2026-05-15 anchor close at $1.98 the packet still did not show a durable post-earnings rerating.

As of 2026-05-16 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q1 milestone-driven beat now has to convert into cleaner underlying commercial demand
Stronger cash balance lowers immediate financing pressure but does not remove biotech runway risk

Scenarios

Bull Target (Scenario probability)

$3 / p=25% prob

Base Target (Scenario probability)

$2 / p=50% prob

Bear Target (Scenario probability)

$1 / p=25% prob

Price $2 as of 2026-05-28

Nearest Scenario: Base (∆ 5%)

Targets vs latest close: Bull +52% · Base +5% · Bear -48%

Sentiment & Exposure

News Sentiment (30d)

58.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2027-09-30
PRX-115 Phase 2 execution remains the main pipeline value driver
Management said the RELEASE Phase 2 study for PRX-115 continues to enroll and still targets topline results in the second half of 2027. Any meaningful enrollment, protocol, or execution update could matter because the pipeline value case still rests mainly on this program and the visibility remains long-dated [#8-K-2026-05-13].
Prob 52.00% • Move 30.00% • Priced-in 22.00%

Short-term Catalysts

Next few weeks

Q1 milestone-driven beat now has to convert into cleaner underlying commercial demand
2026-12-31
The May 13, 2026 earnings release showed Q1 revenue of $33.75 million, net income of $18.3 million, and reaffirmed 2026 revenue guidance of $78.0-$83.0 million, but the quarter was heavily boosted by a $25.0 million Chiesi milestone tied to the EU every-4-weeks Elfabrio regimen. The near-term test is whether recurring Elfabrio and Elelyso sales support that outlook rather than another one-time milestone doing most of the work [#8-K-2026-05-13].
Prob 64% • Move 14% • Priced-in 56%

Long-term Catalysts

Months to a year

Stronger cash balance lowers immediate financing pressure but does not remove biotech runway risk
2027-03-31
Protalix reported $51.1 million of cash, cash equivalents, and short-term bank deposits at March 31, 2026, and said this is sufficient to fund ongoing operations including the Phase 2 RELEASE trial. That is a clear improvement versus year-end, but R&D expense rose 56% year over year to $5.4 million as PRX-115 advanced, so financing sensitivity can return if commercial demand or development timing disappoints [#10-Q-2026-05-13] [#8-K-2026-05-13].
Prob 67% • Move -20% • Priced-in 61%

Risks

Commercial revenue remains concentrated in partners and can be distorted by ordering cadence, especially Pfizer and Chiesi timing.
PRX-115 value realization depends on successful Phase 2 execution with topline data not expected until the second half of 2027.
Q1 profit was milestone-driven, so recurring revenue quality remains less impressive than the headline earnings swing.
R&D spending is rising as RELEASE advances, so the current cash cushion may narrow faster if development timelines slip or commercial uptake underwhelms.
Sell-side coverage is sparse, limiting external validation of guidance, consensus revisions, and post-earnings thesis durability.

Peers

Symbol	Summary
BDTX	Same-sector micro/small-cap biotech comparator by market cap only; useful for financing and event-volatility context, but not a direct read-through for Fabry commercialization or gout development.
SPRO	Another small-cap biotech with binary pipeline sensitivity; still a loose peer because the packet does not establish shared indications, commercial structure, or platform comparability.
MOLN	Market-cap neighbor rather than an operating peer; acceptable only as a sentiment and funding-risk reference, not as a strong valuation comp for PLX.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Human targets: serper
Analysis date: 2026-05-16

AI Stock Memo: PLX - Protalix Biotherapeutics - RankAlpha